These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10197041)

  • 1. Recent progress in the development of tubulin inhibitors as antimitotic antitumor agents.
    Shi Q; Chen K; Morris-Natschke SL; Lee KH
    Curr Pharm Des; 1998 Jun; 4(3):219-48. PubMed ID: 10197041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubulins - the target for anticancer therapy.
    Vindya NG; Sharma N; Yadav M; Ethiraj KR
    Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, antiproliferative activity and molecular docking of thiocolchicine urethanes.
    Majcher U; Urbaniak A; Maj E; Moshari M; Delgado M; Wietrzyk J; Bartl F; Chambers TC; Tuszynski JA; Huczyński A
    Bioorg Chem; 2018 Dec; 81():553-566. PubMed ID: 30248507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Natural Product- and Privileged Scaffold-Based Tubulin Inhibitors Targeting the Colchicine Binding Site.
    Dong M; Liu F; Zhou H; Zhai S; Yan B
    Molecules; 2016 Oct; 21(10):. PubMed ID: 27754459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Tubulin-colchicine Site for Cancer Therapy: Inhibitors, Antibody- Drug Conjugates and Degradation Agents.
    Duan Y; Liu W; Tian L; Mao Y; Song C
    Curr Top Med Chem; 2019; 19(15):1289-1304. PubMed ID: 31210108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural products as antimitotic agents.
    Dall'Acqua S
    Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
    Jordan A; Hadfield JA; Lawrence NJ; McGown AT
    Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiochemical aspects of tubulin-interacting antimitotic drugs.
    Correia JJ; Lobert S
    Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site.
    Li L; Jiang S; Li X; Liu Y; Su J; Chen J
    Eur J Med Chem; 2018 May; 151():482-494. PubMed ID: 29649743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of novel anticancer bivalent colchicine-tubulizine hybrids.
    Malysheva YB; Combes S; Allegro D; Peyrot V; Knochel P; Gavryushin AE; Fedorov AY
    Bioorg Med Chem; 2012 Jul; 20(14):4271-8. PubMed ID: 22739088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational design and biological testing of highly cytotoxic colchicine ring A modifications.
    Torin Huzil J; Winter P; Johnson L; Weis AL; Bakos T; Banerjee A; Luduena RF; Damaraju S; Tuszynski JA
    Chem Biol Drug Des; 2010 Jun; 75(6):541-50. PubMed ID: 20408852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents.
    Xia Y; Yang ZY; Xia P; Hackl T; Hamel E; Mauger A; Wu JH; Lee KH
    J Med Chem; 2001 Nov; 44(23):3932-6. PubMed ID: 11689079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tubulin agents of natural origin: Targeting taxol, vinca, and colchicine binding domains.
    Naaz F; Haider MR; Shafi S; Yar MS
    Eur J Med Chem; 2019 Jun; 171():310-331. PubMed ID: 30953881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer drug design based on plant-derived natural products.
    Lee KH
    J Biomed Sci; 1999; 6(4):236-50. PubMed ID: 10420081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cryptophycin 1 binds to tubulin at a site distinct from the colchicine binding site and at a site that may overlap the vinca binding site.
    Mooberry SL; Taoka CR; Busquets L
    Cancer Lett; 1996 Oct; 107(1):53-7. PubMed ID: 8913266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.
    Lindamulage IK; Vu HY; Karthikeyan C; Knockleby J; Lee YF; Trivedi P; Lee H
    Sci Rep; 2017 Aug; 7(1):10298. PubMed ID: 28860494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Series of Acridinones as Mechanism-Based Tubulin Assembly Inhibitors with Anticancer Activity.
    Magalhaes LG; Marques FB; da Fonseca MB; Rogério KR; Graebin CS; Andricopulo AD
    PLoS One; 2016; 11(8):e0160842. PubMed ID: 27508497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.